Voximetry is proud to announce a product evaluation and research collaboration agreement for Torch® voxel-based Dose Assessment with Fondazione Policlinico Universitario A. Gemelli IRCCS. The collaboration intends to utilize Voximetry’s Torch® software* to research how a radiotherapeutic agent distributes in a specific patient and then report or predict the biologic effect on each tumor or critical organ of interest during therapy.
“Our department is excited to collaborate with Voximetry in order to evaluate the accuracy improvement of dosimetry in radiopharmaceutical therapy. This possibility fits within the concept of personalized medicine and patient-centered, especially in a context in which nuclear medicine therapy is growing with the introduction of new radiopharmaceuticals” states Dr. Amedeo Capotosti, Medical Physicist of Gemelli.
About Fondazione Policlinico Universitario A. Gemelli IRCCS: At the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, there is a strong engagement on the basic, translational and clinical research side with the goal of finding the best personalized therapies for each individual affected by widespread diseases such as cancer, cardiovascular, metabolic and neurological diseases.
About Voximetry, Inc: Voximetry is a Healthtech software company committed to changing the Standard of Care for Radiopharmaceutical Therapy patients by providing advanced dosimetry-guided Radiopharmaceutical Therapy (DG-RPT). Torch® software can help improve patient outcomes by moving beyond population based models and making every treatment personal.*
*510(k) pending. Torch™ is under FDA review and is NOT Available for Sale or Clinical Use